Drug news
FDA accepts re filing of NDA for Macrilen (macimorelin) to treat growth hormone deficiency.- Aeterna Zentaris Inc.
Aeterna Zentaris Inc. announced that it has been notified by the FDA, that the Company�s New Drug Application seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults has been accepted as a complete response to the FDA�s November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.